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It would be appropriate if the authors report on the reveals that the mean T score at the femoral neck was
comparisons between the changes in BMD between the significantly lower than at the lumbar spine (20.89 6 0.32
pamidronate and the placebo group, and if statistically vs. 20.20 6 0.37, P , 0.05). The finding that cortical
insignificant, to report the type II error given the observed osteopenia is greater than cancellous osteopenia in dialysis
differences and the number of subjects, and then to make patients has also been documented by other investigators
a more appropriate conclusion. [2]. Accelerated cortical bone loss driven by secondary
hyperparathyroidism [3, 4] may explain the distribution
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